Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019
Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 5, 6 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Genito Urinary System And Sex Hormones, Central Nervous System, Dermatology, Gastrointestinal, Hormonal Disorders, Infectious Disease and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Solid Tumor, Melanoma, Pancreatic Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Transplant Rejection, Metastatic Melanoma, Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Lupus Nephritis, Lymphoma, Myasthenia Gravis, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Astrocytoma, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Central Nervous System (CNS) Tumor, Diffuse Large B-Cell Lymphoma, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Graft Versus Host Disease (GVHD), Graves Diseases, Head And Neck Cancer, Heart Transplant Rejection, Hematological Tumor, Hepatic (Liver) Tumor, Hidradenitis Suppurativa, Hyperthyroidism, Leiomyosarcoma, Liposarcoma, Liver Transplant Rejection, Malignant Mesothelioma, Mantle Cell Lymphoma, Membranous Glomerulonephritis, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Non-Hodgkin Lymphoma, Pancreatic Islet Transplant Rejection, Pediatric Diffuse Intrinsic Pontine Glioma, Pemphigus, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Soft Tissue Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 5, 6 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Genito Urinary System And Sex Hormones, Central Nervous System, Dermatology, Gastrointestinal, Hormonal Disorders, Infectious Disease and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Solid Tumor, Melanoma, Pancreatic Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Transplant Rejection, Metastatic Melanoma, Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Lupus Nephritis, Lymphoma, Myasthenia Gravis, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Astrocytoma, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Central Nervous System (CNS) Tumor, Diffuse Large B-Cell Lymphoma, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Graft Versus Host Disease (GVHD), Graves Diseases, Head And Neck Cancer, Heart Transplant Rejection, Hematological Tumor, Hepatic (Liver) Tumor, Hidradenitis Suppurativa, Hyperthyroidism, Leiomyosarcoma, Liposarcoma, Liver Transplant Rejection, Malignant Mesothelioma, Mantle Cell Lymphoma, Membranous Glomerulonephritis, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Non-Hodgkin Lymphoma, Pancreatic Islet Transplant Rejection, Pediatric Diffuse Intrinsic Pontine Glioma, Pemphigus, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Soft Tissue Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Development
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Product Development Milestones
Appendix
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Development
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Alligator Bioscience AB, H2 2019
Pipeline by Apexigen Inc, H2 2019
Pipeline by Apogenix AG, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by BioNTech SE, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Celldex Therapeutics Inc, H2 2019
Pipeline by Codiak BioSciences Inc, H2 2019
Pipeline by Denceptor Therapeutics Ltd, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Glycotope GmbH, H2 2019
Pipeline by Kyowa Kirin Co Ltd, H2 2019
Pipeline by Molecular Partners AG, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Symphogen A/S, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Alligator Bioscience AB, H2 2019
Pipeline by Apexigen Inc, H2 2019
Pipeline by Apogenix AG, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by BioNTech SE, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Celldex Therapeutics Inc, H2 2019
Pipeline by Codiak BioSciences Inc, H2 2019
Pipeline by Denceptor Therapeutics Ltd, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Glycotope GmbH, H2 2019
Pipeline by Kyowa Kirin Co Ltd, H2 2019
Pipeline by Molecular Partners AG, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Symphogen A/S, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Alligator Bioscience AB
Apexigen Inc
Apogenix AG
AstraZeneca Plc
Avacta Life Sciences Ltd
BioNTech SE
Boehringer Ingelheim International GmbH
Celldex Therapeutics Inc
Codiak BioSciences Inc
Denceptor Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Glycotope GmbH
Kyowa Kirin Co Ltd
Molecular Partners AG
Novartis AG
Symphogen A/S
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Alligator Bioscience AB
Apexigen Inc
Apogenix AG
AstraZeneca Plc
Avacta Life Sciences Ltd
BioNTech SE
Boehringer Ingelheim International GmbH
Celldex Therapeutics Inc
Codiak BioSciences Inc
Denceptor Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Glycotope GmbH
Kyowa Kirin Co Ltd
Molecular Partners AG
Novartis AG
Symphogen A/S
